AI Engines For more Details: Perplexity Kagi Labs You
Radioprotective Effects: Amifostine is a cytoprotective agent that helps protect normal cells from the harmful effects of radiation therapy. It works by scavenging free radicals and reducing oxidative stress in healthy tissues, thereby minimizing damage to normal cells while preserving the effectiveness of radiation treatment against cancer cells.
Chemoprotective Effects: In addition to its radioprotective effects, amifostine may also have chemoprotective properties. It can help reduce the toxicity of certain chemotherapy drugs, particularly those that cause damage to normal tissues, such as platinum-based drugs (e.g., cisplatin).
Reduction of Xerostomia: One of the most common side effects of radiation therapy to the head and neck region is xerostomia, or dry mouth, due to damage to the salivary glands. Amifostine has been shown to reduce the incidence and severity of xerostomia in patients receiving radiation therapy for head and neck cancer, improving quality of life and reducing the risk of long-term complications such as dental caries.
Nephroprotective Effects: Amifostine may also have nephroprotective effects, helping to protect the kidneys from the toxic effects of certain chemotherapy drugs, such as cisplatin, which can cause kidney damage.
Side Effects: Common side effects of amifostine may include nausea, vomiting, low blood pressure (hypotension), flushing, and transient changes in taste. These side effects are usually mild and temporary and may improve with continued use or dosage adjustments.
Hypersensitivity Reactions: Rarely, amifostine may cause hypersensitivity reactions, including allergic reactions or anaphylaxis. Patients should be monitored closely for signs and symptoms of hypersensitivity, such as rash, itching, swelling, difficulty breathing, or low blood pressure, particularly during the initial administration of amifostine.
Contraindications: Amifostine is contraindicated in patients with known hypersensitivity to the drug or to other thiol compounds. It should be used with caution in patients with cardiovascular disease, hypotension, or renal impairment, as it may exacerbate these conditions.
Administration: Amifostine is typically administered intravenously or subcutaneously shortly before radiation therapy or chemotherapy sessions. The dosage and timing of administration may vary depending on the specific treatment regimen and individual patient factors.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 0.2 | 0.1 | 1 |
| Age-Related Macular Degeneration and Glaucoma | 0.1 | 0.1 | |
| Allergic Rhinitis (Hay Fever) | 0.3 | 0.3 | |
| Allergies | 0.2 | -0.2 | |
| Allergy to milk products | 0.4 | 0.4 | |
| Alzheimer's disease | 0.4 | 0.6 | -0.5 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.1 | 0.1 | 0 |
| Ankylosing spondylitis | 0.4 | -0.4 | |
| Anorexia Nervosa | 0.5 | -0.5 | |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
| Asthma | 0.4 | -0.4 | |
| Atherosclerosis | 0.1 | 0.4 | -3 |
| Atrial fibrillation | 0.4 | 0.3 | 0.33 |
| Autism | 0.6 | 0.6 | 0 |
| Bipolar Disorder | 0.4 | 0.3 | 0.33 |
| Brain Trauma | 0.4 | -0.4 | |
| Carcinoma | 0.4 | 0.4 | 0 |
| Celiac Disease | 0.3 | 0.4 | -0.33 |
| Cerebral Palsy | 0.5 | -0.5 | |
| Chronic Fatigue Syndrome | 0.5 | 0.5 | 0 |
| Chronic Kidney Disease | 0.3 | 0.2 | 0.5 |
| Chronic Lyme | 0.4 | -0.4 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | -0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.2 | -0.2 | |
| Colorectal Cancer | 0.5 | 0.5 | |
| Constipation | 0.3 | 0.1 | 2 |
| Coronary artery disease | 0.1 | 0.1 | 0 |
| COVID-19 | 0.4 | 1.9 | -3.75 |
| Crohn's Disease | 0.6 | 0.6 | 0 |
| cystic fibrosis | 0.4 | -0.4 | |
| deep vein thrombosis | 0.2 | -0.2 | |
| Depression | 1.6 | 0.7 | 1.29 |
| Endometriosis | 0.3 | 0.1 | 2 |
| Epilepsy | 0.3 | 0.3 | 0 |
| Fibromyalgia | 0.1 | 0.4 | -3 |
| Functional constipation / chronic idiopathic constipation | 0.6 | 1.3 | -1.17 |
| gallstone disease (gsd) | 0.1 | 0.1 | 0 |
| Generalized anxiety disorder | 0.3 | -0.3 | |
| Gout | 0.1 | -0.1 | |
| Graves' disease | 0.3 | 0.1 | 2 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.4 | 0.3 | 0.33 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.4 | 0.4 | |
| hyperglycemia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.4 | 0.5 | -0.25 |
| Hypothyroidism | 0.1 | -0.1 | |
| Hypoxia | 0.3 | 0.3 | |
| Inflammatory Bowel Disease | 0.3 | 1 | -2.33 |
| Insomnia | 0.3 | 0.4 | -0.33 |
| Intelligence | 0.1 | 0.1 | |
| Intracranial aneurysms | 0.4 | 0.4 | |
| Irritable Bowel Syndrome | 1.4 | 0.4 | 2.5 |
| Liver Cirrhosis | 0.6 | 0.6 | 0 |
| Long COVID | 1.3 | 0.8 | 0.63 |
| Low bone mineral density | 0.2 | -0.2 | |
| Lung Cancer | 0.9 | 0.1 | 8 |
| ME/CFS with IBS | 0.4 | -0.4 | |
| ME/CFS without IBS | 0.1 | 0.3 | -2 |
| Metabolic Syndrome | 1.4 | 0.6 | 1.33 |
| Mood Disorders | 1.8 | 0.7 | 1.57 |
| Multiple Sclerosis | 0.1 | 0.5 | -4 |
| Multiple system atrophy (MSA) | 0.1 | -0.1 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | -0.4 | |
| Obesity | 1.4 | 0.4 | 2.5 |
| obsessive-compulsive disorder | 0.5 | 0.3 | 0.67 |
| Osteoarthritis | 0.3 | 0.1 | 2 |
| Osteoporosis | 0.4 | 0.3 | 0.33 |
| Parkinson's Disease | 0.1 | 0.6 | -5 |
| Polycystic ovary syndrome | 0.4 | 0.3 | 0.33 |
| Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
| Psoriasis | 0.1 | 0.5 | -4 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.6 | 0.5 | 0.2 |
| Rosacea | 0.1 | 0.1 | 0 |
| Schizophrenia | 0.4 | 0.3 | 0.33 |
| scoliosis | 0.1 | 0.1 | 0 |
| Sjögren syndrome | 0.3 | -0.3 | |
| Sleep Apnea | 0.2 | 0.5 | -1.5 |
| Stress / posttraumatic stress disorder | 0.4 | 0.5 | -0.25 |
| Systemic Lupus Erythematosus | 0.3 | 0.2 | 0.5 |
| Tic Disorder | 0.1 | 0.1 | |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 0.4 | 0.1 | 3 |
| Type 2 Diabetes | 1.4 | 0.6 | 1.33 |
| Ulcerative colitis | 0.3 | 0.5 | -0.67 |
| Unhealthy Ageing | 0.3 | 0.2 | 0.5 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.